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Orexins/hypocretins are neuropeptides implicated in numerous processes, including food intake and 
cognition. The role of these peptides in the psychopathology of anorexia nervosa (AN) remains poorly 
understood. The aim of the current study was to evaluate the associations between plasma orexin-A 
(OXA) concentrations and neuropsychological functioning in adult women with AN, and a matched 
control group. Fasting plasma OXA concentrations were taken in 51 females with AN and in 51 matched 
healthy controls. Set-shifting was assessed using the Wisconsin Card Sorting Test (WCST), whereas 
decision making was measured using the Iowa Gambling Task (IGT). The AN group exhibited lower 
plasma OXA levels than the HC group. Lower mean scores were obtained on the IGT in AN patients. 
WCST perseverative errors were significantly higher in the AN group compared to HC. In both the AN 
and HC group, OXA levels were negatively correlated with WCST non-perseverative errors. Reduced 
plasma OXA concentrations were found to be associated with set-shifting impairments in AN. Taking 
into consideration the function of orexins in promoting arousal and cognitive flexibility, future studies 
should explore whether orexin partly underpins the cognitive impairments found in AN.
Anorexia nervosa (AN) is a psychiatric disorder characterized by low body weight, severely restricted eating 
behavior, an extreme pursuit of thinness and an intense fear of weight gain1. In addition to the above-mentioned 
symptoms, patients with AN have repeatedly been found to present altered performance on neuropsychological 
tasks examining decision-making2,3, set-shifting4, central coherence5, and delay discounting6,7. There is also strong 
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evidence to support that alterations in reward processing in AN patients are underpinned by altered reactivity in 
striatal regions8 and to the possibility of hypothalamic inputs being overridden by top-down emotional-cognitive 
control regions9. Additionally, innovative new lines of research suggest that increased activations in fronto-striatal 
circuits are strongly associated with the maintenance of restrictive eating habits in AN patients10. These deficits 
in executive functioning are thought to contribute to the severity of the disorder and hinder the effectiveness of 
treatment by encouraging reduced food intake, body image distortions, and rigid thinking styles11. Indeed, recent 
findings indicate that the undernourished state of AN may amplify the tendency to forgo immediate rewards in 
favor of longer-term goals, thereby perpetuating the symptoms of AN12.
Orexin-A (OXA), also known as hypocretin 1, is a neuropeptide synthesized in the hypothalamus that is 
implicated in the regulation of an array of complex behaviors, including sleep/wakefulness, reward, food intake, 
and cognition13–16. Although OXA neurons were until recently thought to be restricted to the lateral hypothala-
mus, studies have found that orexinergic fibers are extensively distributed in numerous brain regions, including 
the posterior hypothalamus and perifornical areas17. Orexins are increasingly understood to play a significant 
role in the pathology of psychiatric disorders18, narcolepsy-cataplexy19, neurodegenerative diseases, such as 
Alzheimer’s disease20, and in controlling energy homeostasis21,22. In the specific case of AN, results thus far have 
been inconsistent with studies finding plasma OXA levels in patients with AN to be higher23, lower24, or not sig-
nificantly different in comparison to healthy controls (HC)25. Though few longitudinal studies have carried out 
in AN patients, it appears that OXA levels decrease following weight restoration23,24. However, it must be noted 
that these studies had relatively small sample sizes and did not follow patients for a long enough time span for full 
recovery to be reached. OXA levels in AN patients may also potentially be influenced by the diurnal intermittent 
fasting that is characteristic of the disorder26. Such fluctuations in OXA concentrations could have downstream 
effects on wakefulness14 and response to salient cues27, thereby influencing executive functioning.
Orexins are believed to be involved in higher cognitive functions due to their role in maintaining the excit-
ability of pyramidal neurons in the prefrontal cortex18. One study determined elevated orexins in female rats 
following repeated exposure to stress to be linked to stress-induced cognitive deficits in the side reversal task of 
Attentional Set Shifting Test28. Likewise, the preclinical literature has consistently suggests that orexins enhance 
cognitive function, whereas orexin antagonists lead to impairments in different types of cognitive function, such 
as attention, spatial memory, and social memory29. Taking into consideration the aforementioned importance of 
cognition in treatment response, it would be of great interest to determine the associations between neurocogni-
tive performance and OXA levels in patients with AN. Such findings could shed light on the emerging role of the 
orexinergic system in the pathophysiology of AN30.
Methods
Participants and procedure. Participants in this study included 51 women with AN (BMI < 18.5 kg/m2) 
and 51 matched female healthy controls (HC; BMI = 18.5–24.9 kg/m2). 65.8% of the sample included in this study 
was featured in Sauchelli et al.25. AN participants were consecutively recruited from the Department of Psychiatry 
at Bellvitge University Hospital (Barcelona, Spain) and were diagnosed by means of structured face-to-face inter-
view, following DSM-5 criteria31. All diagnoses were established using an adapted version of the structured clin-
ical interview for DSM-IV (SCID-I)32.
Participants were excluded if they were under 18 or over 60 years of age. Males were excluded from the study 
given the low prevalence of male AN patients in our sample. Several centers belonging to our Spanish Research 
Network (CIBEROBN) participated in this project. The HC group was a convenience sample (matched for age 
and education level) recruited via word-of-mouth and advertisements. To be eligible for the HC group, partici-
pants could not have a lifetime history of an eating disorder and current obesity.
As described previously16,25, clinical and physical assessments were conducted by experienced psychologists, 
psychiatrists and endocrinologists. Self-report questionnaires were completed as part of the evaluation process 
at the start of treatment. Patients with AN were voluntarily undergoing day-hospital treatment and all measures 
were collected upon admission to treatment. All participants completed the same self-reported questionnaires 
to coincide with the blood sample extraction. Anthropometric information was obtained using a bioimpedance 
scale.
All participants provided signed informed consent. The University Hospital of Bellvitge Ethics Committee 
of Clinical Research, the Hospital Universitari de Girona Doctor Josep Trueta Comitè Ètic d’Investigació 
Clínica, the Parc de Salut Mar Comitè Ètic d’Investigació Clínica, the Hospital Universitario Virgen de la 
Victoria Subcomisión de Investigación Clínica, Universidad de Navarra Comité de Ética de la Investigación, 
and the Comissió Deontológica de la Universitat Jaume 1 approved the study, conducted in accordance with the 
Declaration of Helsinki.
Measures. Orexin-A plasma concentrations. Peripheral blood samples were collected from all partici-
pants after an overnight fast. Blood was drawn from an antecubital vein using a 10 mL ethylenediamietraacetic 
acid (EDTA) containing BD Vacutainer® tube. Samples were centrifuged at 3130 × g for 15 min at 4 degrees 
Celsius (°C). Plasma and serum were distributed in aliquots and stored at 80 (°C) until analysis. Several 
plasma bio-chemical variables were measured in duplicate. OXA/hypocretin-1 was measured using a Phoenix 
Pharmaceuticals Inc. EIA kit (Burlingame, California, USA). Multiple studies have demonstrated that it features 
a wide detection range, between 0–100 ng/mL, with a linear range of 0.2–2.66 ng/mL, a sensitivity of 0.2 ng/ml, an 
intra-assay variation <10%, and an inter-assay variation <15%. Our data provide a linear range of 0.30–3.08 ng/
mL, a detection limit of 0.16 ng/ml, an intra-assay variation of 9.52% and an inter-assay variation of 13.70%. 
With respect to its specificity, this kit does not have cross-reactivity with OXA (16–33), orexin B (human), 
agouti-related protein (83–132)-amide (human), neuropeptide (human, rat), α-MSH (human, rat, mouse) and 
leptin (human). We did not analyze cross-reactivity with any other molecule.
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Anthropometric measures. A Tanita BC-420MA was utilized to measure body composition and to calculate 
BMI. This noninvasive and validated device (Tanita BC-420MA) uses bioelectrical impedance analyses to obtain 
weight and body composition variables33. Height was taken via a stadiometer.
The Wisconsin card sorting test (WCST). The WCST34 is a widely used measure to assess an individual’s capacity 
to plan, control impulsive responses, and be flexible under changing conditions. During this task, participants 
must match a target card with one of four category cards. After each trial, feedback is given to the participant, 
indicating whether they have matched the card appropriately. However, the classification rule for matching cards 
with categories changes during the task and participants must shift and update their previous strategy to perform 
well on the task. The test ends when the participant has completed six categories or 128 trials. A computerized 
version of the task was used for this study35.
The iowa gambling task (IGT). The IGT36,37 is a commonly used measure of decision-making ability. During this 
task, participants must choose from four decks of cards (A, B, C and D) and each time the participant selects a 
deck, a specified amount of play money is awarded. The interspersed rewards among theses decks feature proba-
bilistic punishments (monetary losses with varying amounts). Decks A and B are not advantageous as losses are 
higher than gains; whereas, decks C and D are advantageous since the punishments are smaller. This test is scored 
by subtracting the number of cards selected from decks A and B from the number of cards selected from decks C 
and D. Higher scores demonstrate better performance on the task while negative scores are indicative of choosing 
disadvantageous decks.
General psychopathology. The Symptom Checklist-revised (SCL-90-R)38 was used to explore general psychopa-
thology. This 90-item, self-report questionnaire is answered on a five-point Likert scale. The items are grouped 
into nine primary symptom dimensions and it provides a global severity index (GSI) to indicate overall distress. 
The test has been validated in a Spanish population39, with a mean internal consistency of 0.75 (alpha coefficient).
Eating disorder symptomatology. The Eating Disorder Inventory-2 (EDI-2)40 was used to examine eating disor-
der severity. This test, consisting of 91 items, each rated on a six-point Likert scale, evaluates eleven cognitive and 
behavioral characteristics observed in people with eating disorders. A total score is also provided to report overall 
eating disorder severity. This instrument has been validated in Spanish-speaking populations41 with a mean inter-
nal consistency of 0.63 (alpha coefficient).
Statistical analysis. Statistical analysis was carried out with Stata15 for Windows. Comparisons of means 
between groups (AN and HC) was based on analysis of variance (ANOVA). Associations between neuropsycho-
logical variables and orexin levels were estimated with correlation coefficients. In this study, due to the strong 
association between neuropsychological performance with age and education levels, these two variables were 
defined as covariates in the statistical analysis. Effect size was measured through Cohen’s-d coefficient for mean 
differences (|d| > 0.2 was considered low effect size, |d| > 0.5 was considered moderate and |d| > 0.8 was consid-
ered large)42. For the correlation estimates, and due to the strong association between this model and sample size, 
relevance was based on coefficient measures (|R| > 0.10 was considered low effect size, |r| > 0.24 was considered 
moderate and |r| > 0.37 was considered large)43. Finner’s method controlled for increases in Type-I error due to 
multiple statistical comparisons (this procedure is included in the Family-wise error rate stepwise procedures and 
provides a more powerful test than Bonferroni correction)44.
Results
Sample description and comparison between OXA, body composition and neuropsychological 
measures. Table 1 contains a description of the study variables, as well as comparisons between the groups. 
As mentioned above, HC were chosen to match their AN counterparts with respect to age and years of educa-
tion and no differences were found between groups in these variables (p = 0.666 and p = 1.000, respectively). As 
expected, patients with AN exhibited significantly higher levels of psychopathology as measured by the SCL-90-R 
GSI score and higher levels of total eating disorder severity on the EDI-2.
Table 1 also contains the results of the ANOVA, adjusted for age and education level, comparing the mean 
scores between the groups. The AN group exhibited lower BMI and body fat mass % than the HC group. Lower 
means were obtained on all the IGT measures (except for block 1) in AN patients. WCST perseverative errors 
were significantly higher in the AN group compared to HC.
Correlation analysis. Table 2 contains the partial correlation matrix (coefficients adjusted for age, educa-
tion and BMI) measuring the association between the neuropsychological measures and plasma OXA levels. 
Taking into account previous studies indicating an association between clinical state and neuropsychological 
performance2, we chose to run our correlational analyses including BMI as a covariate. Negligible differences in 
the results were found when BMI was not included as a covariate. In the AN group, OXA levels were negatively 
correlated with IGT block 1 performance, WCST number of trials, WCST errors and WCST non-perseverative 
errors. In the HC group, OXA levels were positively correlated with IGT block 4 scores and negatively correlated 
with WCST non-perseverative errors. Figure 1 presents a scatterplot of OXA levels and WCST non-perseverative 
errors in both groups and the whole sample. Regarding the potential associations between the measures of ED 
severity (EDI-2 total raw scores) and psychopathology (SCL-90R GSI) with OXA levels, the bottom of the Table 2 
contains these partial correlations, whose effect sizes were in the low/null range.
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Discussion
In this study, we examined the association between OXA levels and cognitive impairments in patients with AN. 
Our findings indicate that OXA levels in AN patients were significantly lower than in HCs, though, it should be 
noted that diverging results in other AN samples have been found23. These discrepancies could stem from the 
numerous differences in the characteristics of the patients featured in the study at hand and other studies. For 
example, our study included patients with both AN restrictive subtype and binge-eating/purging subtype. One 
study utilizing an animal model of binge eating found that orexin antagonists reduced binge eating episodes 
Anorexia (n = 51) Control (n = 51)
Mean SD Mean SD p |d|
Age (years) 27.43 8.65 26.75 7.32 0.666 0.09
EDI-2 total score 78.78 43.72 22.59 16.91 0.001* 1.70†
SCL-90-R GSI 1.48 0.74 0.56 0.39 0.001* 1.56†
Plasma orexin-A levels (pg/
ml) 2.43 0.82 2.99 0.67 0.001* 0.75
†
BMI (kg/m2) 17.11 1.27 21.37 1.81 0.001* 2.73†
Body fat mass (%) 6.37 3.11 15.32 4.42 0.001* 2.34†
1IGT Block 1 (raw score) −1.95 4.20 −2.44 7.48 0.714 0.08
1IGT Block 2 (raw score) −0.77 4.41 5.69 8.35 0.001* 0.97†
1IGT Block 3 (raw score) −0.20 5.36 7.01 8.48 0.001* 1.02†
1IGT Block 5 (raw score) 0.42 6.69 9.30 9.28 0.001* 1.10†
1IGT Block 6 (raw score) 0.79 9.26 6.80 10.61 0.007* 0.60†
1IGT Total (raw score) −1.71 21.06 26.36 27.82 0.001* 1.14†
1WCST Trials (raw score) 92.51 18.05 86.96 16.32 0.182 0.32
1WCST Correct (raw score) 65.67 12.39 66.98 6.92 0.547 0.13
1WCST Errors (raw score) 26.91 17.19 19.99 17.52 0.152 0.40
1WCST perseverative errors 
(raw score) 13.57 9.87 9.53 5.22 0.045* 0.51
†
1WCST non-perseverative 
errors (raw score) 13.33 16.99 10.46 11.41 0.350 0.20
1WCST conceptual (raw 
score) 57.90 18.90 61.76 11.33 0.250 0.25
Table 1. Sample description and comparison between groups in orexin levels, body composition and 
neuropsychological performance. Note. 1Results adjusted for age and education level. SD: standard deviation. 
*Bold: significance (0.05 level). †Effect size in the moderate (|d| > 0.50) to high range (|d| > 0.80). p-value 
includes Finner’s correction for multiple statistical comparisons. EDI-2: The Eating Disorder Inventory-2; SCL-
90-R: The Symptom Checklist-revised; BMI: body mass index; IGT: Iowa Gambling Task; WCST: Wisconsin 
Card Sorting Test.
Anorexia (n = 51)
Control 
(n = 51)
IGT Block 1 (raw score) −0.331† −0.097
IGT Block 2 (raw score) 0.089 0.142
IGT Block 3 (raw score) 0.104 0.205
IGT Block 4 (raw score) 0.080 0.241†
IGT Block 5 (raw score) 0.136 0.175
IGT Total (raw score) 0.060 0.226
WCST Trials −0.300† −0.206
WCST Correct −0.041 0.088
WCST Errors −0.241† −0.227
WCST perseverative errors 0.014 −0.172
WCST Non-perseverative 
errors −0.371
† −0.246†
WCST Conceptual 0.126 0.200
EDI-2 total score 0.068 0.021
SCL-90-R GSI 0.078 −0.027
Table 2. Associations between neuropsychological measures with orexin levels (pg/ml): partial correlations 
(adjusted for age, education level and BMI). Note. †Effect size in the moderate (|r| > 0.24) to high range 
(|r| > 0.37). IGT: Iowa Gambling Task; WCST: Wisconsin Card Sorting Test.
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preceded by stress and dietary restriction, suggesting that orexin could play distinctive role in AN patients that 
binge eat45. Other potential confounding factors include the effects of intermediate fasting26, sleep patterns46, and 
pharmacological treatment47. Recent research has also illustrated how insufficient up-regulation of orexin (Hcrt) 
genes during activity-based anorexia contributes to greater suppression of food intake and greater body weight 
loss in prenatal stress (PNS) exposed rats. This suggests that OXA may be useful for the discovery of biomarkers 
of weight loss vulnerability in order to gain a better understanding of neural circuits implicated in AN pathol-
ogy30,48. Still, longitudinal studies are needed to determined whether such alterations in OXA are present before 
the onset of AN and after long-term recovery.
We also identified a significant correlation between non-perseverative errors on the WCST and orexin levels 
in both the AN and HC group. Non-perseverative errors are indicative of an inability to discern patterns and 
detect favorable choice. Our finding dovetails with the results of a recent study demonstrating that intra-basal 
forebrain infused OXA facilitated both the acquisition and reversal portions of an olfactory discrimination task49. 
Similarly, increased levels of OXA have been linked to fewer perseverative errors and reduced negative symptoms 
in patients with schizophrenia50 compared to patients with lower orexin levels. Taking into consideration the 
function of orexins in promoting arousal and responding to stress, it could be posited that reduced OXA activity 
could partly underpin the cognitive impairments found in AN51,52.
In line with past research, we also identified decision-making deficits in patients with AN using the IGT2,3. 
Poor decision-making is known to be more pronounced during the acute phase than in the recovered state of AN2 
and it would be of interest to explore whether such improvements coincide with changes in OXA levels. In the 
study at hand, OXA levels only negatively correlated with scores from the first block of the task in AN patients, 
but not with overall performance. Other studies have attempted to use intranasal administration of orexin pep-
tides for age-related cognitive dysfunction53 and it may be of clinical interest to explore the possibility of using 
OXA to potentially offset the cognitive deficits found in certain psychiatric disorders54 or accompanying aging55. 
However, more basic research would be needed before such an endeavor could be undertaken.
This study must be interpreted in light of its limitations. For instance, diverging reports of increased or 
decreased levels of OXA in AN may result from sample heterogeneity (i.e. AN subtype, age and weight status). 
Another potential limitation of our study is the use of measured plasma OXA levels as a proxy for central orexin 
system activity. There is evidence in rodent studies to infer that OXA crosses the blood brain barrier56,57 and that 
the OXA plasma levels in humans are indicative of peptide release from both the brain and the gut58. However, 
no direct measure of CNS orexin levels were taken due to the high levels of invasiveness this procedure would 
entail. The kit used in this study could have other cross-reactivity than those mentioned by manufacturer. In this 
sense, we have not analyzed cross-reactivity with other molecules. However, our study does not intend to analyze 
this factor nor be a validation study of a kit that is already on the market and that has been widely used in other 
studies. Furthermore, no conclusions regarding causality can be made from our findings given the cross-sectional 
nature of our study. There is previous research to support that orexin levels could may in fact further decrease 
with treatment23,24, and it would be useful to examine orexin levels in individuals who have obtained full recov-
ery from AN. Lastly, recent work has identified that orexins are regulators of sex differences in the behavioral 
adaptations to- and consequences of repeated stress28. Therefore, it would be beneficial for future studies to assess 
sex-related differences in orexin system functioning in patients with AN.
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